Does Empagliflozin Modulate Leukocyte–Endothelium Interactions, Oxidative Stress, and Inflammation in Type 2 Diabetes?

Does metformin modulate mitochondrial dynamics and function in type 2 diabetic patients?

(2021) Aranzazu Martinez de Marañón et al.   ANTIOXIDANTS & REDOX SIGNALING

Empagliflozin protects heart from inflammation and energy depletion via AMPK activation

(2020) Chintan N. Koyani et al.   PHARMACOLOGICAL RESEARCH

The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes

(2019) Francesca Iannantuoni et al.   Journal of Clinical Medicine

Malnutrition impairs mitochondrial function and leukocyte activation

(2019) Celia Bañuls et al.   Nutrition Journal

Diabetes, cardiovascular disease and the microcirculation

(2018) W. David Strain et al.   Cardiovascular Diabetology

Empagliflozin: A Review in Type 2 Diabetes

(2018) James E. Frampton   DRUGS

EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus

(2016) Guntram Schernthaner et al.   CLINICAL THERAPEUTICS

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)

(2015) T. R. Pieber et al.   DIABETES OBESITY & METABOLISM

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

(2014) Hans-Ulrich Häring et al.   DIABETES CARE

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes

(2014) Michael Nauck   Drug Design Development and Therapy